Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319318 · ClinicalTrials.gov registry record
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 25
- Enrollment target
NCT01319318: Completed study, sponsored by Allergan.
NCT01319318 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01319318 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
Primary Outcome
The study eye was dilated and the investigator used an instrument to count the number of visible cells in the vitreous, the jelly-like fluid that fills the back of the eye, using the following scale: 0 (no cells) best, +1 (1-10 cells), +2 (11-30 cells), +3 (31-50 cells) and +4 (\>50 cells) worst.
Interventions
- PROCEDURE Pars Plana Vitrectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-06 |
What the finished NCT01319318 record still lists
NCT01319318 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pars Plana Vitrectomy is the first listed.
NCT01319318 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01319318 about?
NCT01319318 is a clinical study titled "Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy". This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
What is the current status of trial NCT01319318?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2011-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01319318?
The interventions under investigation include: Pars Plana Vitrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT01319318?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia